Indusatumab vedotin (MLN-0264) is an
antibody-drug conjugate that is under development for the treatment of
pancreatic cancer
Pancreatic cancer arises when cell (biology), cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a Neoplasm, mass. These cancerous cells have the malignant, ability to invade other parts of t ...
and other
gastrointestinal cancer
Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The ...
s.
It consists of a
monoclonal antibody (indusatumab) that targets the enzyme
guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the
chemotherapeutic agent
monomethyl auristatin E (MMAE).
It was in
Phase II clinical trials . The trials were terminated in 2017 because of insufficient efficacy.
References
{{monoclonal-antibody-stub
Experimental drugs
Experimental cancer drugs